Myopia outcome study of atropine in children: Two-year result of daily 0.01% atropine in a European population.
James J LoughmanEmmanuel Kobia-AcquahGareth LinghamJohn B ButlerEkaterina LoskutovaDavid A MackeySamantha Sze-Yee LeeDaniel Ian FlitcroftPublished in: Acta ophthalmologica (2023)
Atropine 0.01% was safe, well-tolerated and effective in slowing axial elongation in this European population. Treatment efficacy varied by ethnicity and eye colour, and potentially by degree of COVID-19 public health restriction exposure during trial participation.